At a glance
ClinicalIndex Comparison Record- ✓Age 18–80 years with diagnosed WHO Group I pulmonary arterial hypertension
- ✓Must have previously implanted CardioMems continuous PA pressure monitoring device
- ✓Ambulatory and able to complete 6-minute walk distance test
- ✕Pregnant or lactating females
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of iNO on Invasively Derived Pulmonary Vascular Parameters in Patients With Pulmonary Arterial Hypertension
In Brief
A Phase 2 clinical trial evaluating Nitric Oxide for Pulmonary Arterial Hypertension. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Pulmonary hypertension is characterized by an increase in the pressures in the blood supply to the lungs greater than a mean pressure of 25mmHg and a concomitant increase in overall pulmonary vascular resistance (PVR). In patients who have remodeling of their pulmonary vasculature, PVR will increase with exercise instead of decreasing as it would in normal patients. Based on published evidence, the investigators intend to investigate the effects of inhaled nitric oxide (iNO) on patients undergoing standard exercise techniques who have separately and previously had an implanted pulmonary artery monitoring device (CardioMems by St Jude Medical, Inc.) placed.
Study Details
Timeline
Interventions
Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test